Pharmacokinetic study of pleural fluid penetration of carbapenem antibiotic agents in chemical pleurisy  by Niwa, Toshiaki et al.
ARTICLE IN PRESSRespiratory Medicine (2006) 100, 324–331KEYWORD
Carbapene
antibiotic
Penetratio
Pleurisy;
Turpentine
Rabbit
0954-6111/$ - s
doi:10.1016/j.r
Abbreviation
dehydropeptida
maximum conc
Correspond
E-mail addrPharmacokinetic study of pleural fluid
penetration of carbapenem antibiotic agents in
chemical pleurisy
Toshiaki Niwa, Atsushi Nakamura, Takashi Kato, Takeo Kutsuna,
Ken Katou, Hiroki Morita, Yasuhiro Kojima, Makoto ItohDepartment of Internal Medicine and Bioregulation, Nagoya City University Graduate School of Medical
Sciences, 1 Kawasumi, Mizuho-cho Mizuho-ku, Nagoya 467-8602, Japan
Received 27 October 2004; accepted 2 May 2005S
m
agent;
n;
oil;
ee front matter & 2005
med.2005.05.009
: IPM ¼ imipenem; PAP
se-I; HPLC ¼ high-perf
entration of drug in ser
ing author. Tel.: +81 52
ess: toniwa@med.nagoySummary
Study objectives: We investigated pleural fluid penetration of carbapenem
antibiotic agents [imipenem (IPM), panipenem (PAPM), meropenem (MEPM), and
biapenem (BIPM)] using an experimental rabbit pleuritis model to clarify the
usefulness of the carbapenem agents for the treatment of bacterial pleurisy or
pyothorax.
Measurements and results: Serum and pleural fluid specimens were serially
collected at 5, 10, 15, 30, 60, 90, 120, 180, 240, 300, and 360min after antibiotic
administration for measurement of antibiotic levels. We investigated each agent
alone as well as drug solutions containing each agent and a dehydropeptidase-I-
specific inhibitor, cilastatin (CS), to remove the influence of dehydropeptidase-I-
related hydrolysis. Groups of animals ðn ¼ 3Þ received each carbapenem agent with
or without CS. Serum and pleural fluid antibiotic levels were measured by high-
performance liquid chromatography (HPLC). Because Cmax is not useful for
evaluating the antimicrobial effects of carbapenem antibiotic agents due to their
dose-dependent antimicrobial activity, we also investigated the AUC, which is
correlated with the total drug levels in vivo.
Among the drug solutions containing CS, MEPM/CS had the highest pleural fluid
AUC0–360 (1594.87510.3 mgmin/ml), and the highest pleural fluid AUC0–360/plasma
AUC0–360 ratio (0.7970.04). BIPM/CS had the highest plasma AUC0–360
(3040.171525.9 mgmin/ml). In pleural fluid AUC0–360/plasma AUC0–360 ratio MEPM/
CS was significantly higher than those for the remaining agents. In pleural fluidElsevier Ltd. All rights reserved.
M ¼ panipenem; MEPM ¼ meropenem; BIPM ¼ biapenem; CS ¼ cilastatin; DHP-I ¼
ormance liquid chromatography; AUC ¼ area under the concentration–time curve; Cmax ¼
um and pleural fluid.
853 8211; fax: +81 52 852 0952.
a-cu.ac.jp (T. Niwa).
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Pharmacokinetic study of pleural fluid penetration of carbapenem 325AUC0–360 and plasma AUC0–360 there were no significant differences among these
mixed solutions.
Conclusions: MEPM had the most favorable pleural fluid penetration. Pleural fluid
penetration should be examined in infection models and in clinical trials.
& 2005 Elsevier Ltd. All rights reserved.Introduction
Mixed infection, in which causative bacteria in-
clude gram-positive or gram-negative bacteria as
well as anaerobic bacteria, occurs in many patients
with bacterial pleurisy or pyothorax. In these cases,
carbapenem antibiotic agents are frequently ad-
ministered. To cure the infection, antimicrobial
agents are commonly administered for a longer
period than for other respiratory infections such as
pneumonia. Administration of ineffective antibio-
tics for a long period causes the emergence of
antibiotic-resistant bacteria. To prevent the emer-
gence of antibiotic-resistant bacteria it is necessary
to administer antibiotics that have good antimicro-
bial spectra and good penetration of the target
organ. Some studies1–3 have examined the pene-
tration of carbapenem antibiotic agents into the
thoracic cavity in patients with carcinomatous
pleurisy and tuberculous pleurisy; no studies have
compared intrathoracic penetration among these
agents under the same conditions. Although some
studies4–6 using various experimental models of
empyma have been done, we think that frequent
collection of pleural fluid and measurements of
pleural fluid using high-performance liquid chro-
matography (HPLC) are difficult in infection models
without chemical inducers. In pleural infections,
pleural fluids evolve in stages from the simple
parapneumonic pleural effusions to pyothorax.7,8
Penetration of the pleura in each stage is different.
Therefore, we investigated the pharmacokinetics
of the carbapenem antibiotic agents in turpentine
oil-induced chemical pleurisy for the preliminary
step of the exudates pleuritis.Materials and methods
Animals
Twenty-seven Japanese white male rabbits weigh-
ing 2.5–3.5 kg were purchased from Kitayama Labes
(Nagano, Japan). Animals were allowed free access
to water and a standard laboratory diet. The study
design was approved by the Animal Care Committee
of Nagoya City University.Experimental pleurisy
We prepared a turpentine oil-induced chemical
model of pleurisy, as described by Sahn et al.9
Rabbits were anesthetized with pentobarbital
sodium salt (25mg/kg intravenously). An 18-gauge
catheter was transfixed into the left thoracic cavity
using the modified Seldinger technique. Turpentine
oil (0.4ml/kg) and 0.2ml of air were infused
through the catheter, and each rabbit was rotated
for approximately 1min to induce pleurisy. Our
experiment was performed 48 h after the infusion
of turpentine oil.
Antibiotic agents
Carbapenem antibiotic agents, imipenem (IPM),
panipenem (PAPM), meropenem (MEPM), and bia-
penem (BIPM), were supplied by Merck USA. Inc.,
Sankyo Co., Ltd., Tokyo Japan, Sumitomo Pharma-
ceuticals Osaka, Japan, and Meiji Seika Kaisha,
Ltd., Osaka, Japan, respectively.
The dehydropeptidase-I (DHP-I) inhibitor, cilas-
tatin (CS), was supplied by Merck USA. Inc.
Collection of blood and pleural fluid samples
After confirmation of the existence of pleural fluid
by direct puncture, each carbapenem antibiotic
agent (IPM, PAPM, MEPM, or BIPM, 20mg/kg) was
administered through the ear vein. Approximately
1.0ml of blood was serially collected at 5, 10, 15,
30, 60, 90, 120, 180, 240, 300, and 360min after
administration of a carbapenem antibiotic agent
through the contralateral ear vein. Simultaneously,
approximately 0.5ml of pleural fluid was collected
at 5, 10, 15, 30, 60, 90, 120, 180, 240, 300, and
360min after administration of a carbapenem
antibiotic agent with a heparinized syringe from
the thoracic cavity into which the turpentine oil
was infused. Groups of animals ðn ¼ 3Þ received
each carbapenem agent.
Carbapenem antibiotic agents are hydrolyzed by
DHP-I, a type of dipeptidase.10 Therefore, we
investigated each agent alone as well in drug
solutions containing each agent and a CS, DHP-I-
specific inhibitor,11 to remove the influence of DHP-
I-related hydrolysis [IPM/CS, PAPM/CS, MEPM/CS,
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of animals ðn ¼ 3Þ received each carbapenem agent
with CS.
Blood and pleural fluid were sampled just before
(baseline) the administration of each antibiotic
agent.Storage of samples
Blood samples were collected, treated with hepar-
in, and centrifuged in a refrigerated centrifuge
(4 1C 3000 rpm 10min) to separate plasma. Plas-
ma samples were mixed with an equivalent volume
of various stabilizing agents (Table 1), and snap-
frozen/stored at 80 1C. Similarly, pleural fluid
was centrifuged in a refrigerated centrifuge (4 1C
3000 rpm 10min). The supernatant was mixed
with an equivalent volume of stabilizing agents
as described above, and snap-frozen/stored at
80 1C.Measurement of drug levels
The samples were centrifuged with ultrafiltration
devices (Amicon Centrifree; WR Grace & Co; Beverly,
MA) with a molecular weight cutoff of 30,000 in a
refrigerated centrifuge (4 1C 3000 rpm 15min). The
filtrate was collected, and drug levels were mea-
sured by HPLC. The HPLC instrumentation (Waters,
Milford, MA) consisted of a model 600E pumping
system, a model 717 automatic injector, a model
2487 ultraviolet detector, and a Millennium32 Chro-
matography Information System capable of providing
peak retention times, areas, and heights.
The conditions of HPLC used for assays of IPM were
as follows: a column, STR-ODS-II, 250mm 4.6mm
I.D. (Shimadzu Techno-Research, Kyoto, Japan); a
mobile phase: a mixture of 0.2M borate buffer (pH
7.2)/methanol (97:3, by vol); a flow rate of 0.7ml/Table 1 The stabilizations of carbapenem anti-
biotic agents.
Antibiotics Stabilization (v/v)
IPM 1M morpholino-ethane sulfonic
acid (pH 6.0):100% ethylene glycol
1:1
PAPM 1M morpholino-propane sulfonate
(pH 7.0) (MOPS)
MEPM None
BIPM 50% ethylene glycol: 1M
morpholino-propane sulfonate (pH
7.0) (MOPS) 1:1min; and a wavelength of 298nm. The injection
volume was 10mL. The lower limit of detection was
0.25mg/ml in plasma and pleural fluid. (These
methods were referred to those of Banyu Pharma-
ceutical Co., Ltd.)
The conditions of HPLC used for assays of PAPM
were as follows: a column, YMC-PAC A-312 ODS,
150mm 6.0mm I.D. (YMC Co., Ltd., Kyoto,
Japan); a mobile phase: a mixture of acetonitrile/
methanol/ammonium acetate (pH 5)/PIC B7
(1:6:92:1, by vol); a flow rate of 1.5ml/min; and
a wavelength of 290 nm. The injection volume was
20 mL. The lower limit of detection was 0.3 mg/ml in
plasma and pleural fluid.12
The conditions of HPLC used for assays of MEPM
were as follows: a column, SUMIPAX Hypersil ODS,
150mm 4.6mm I.D. (Sumika Chemical Analysis
Service, Osaka, Japan); a mobile phase: a mixture
of PIC A (Low UV 5mM)/methanol (77:23, by vol); a
flow rate of 1.0ml/min; and a wavelength of
300 nm. The injection volume was 50 mL. The lower
limit of detection was 0.05 mg/ml in plasma and
pleural fluid. (These methods were referred to
those of Sumitomo Pharmaceutical Co., Ltd.)
The conditions of HPLC used for assays of BIPM
were as follows: a column, TSK gel ODS 80TM,
250mm 4.6mm I.D. (Tosoh, Co., Ltd., Tokyo,
Japan); a mobile phase: a mixture of 0.1M acetate
buffer/acetonitrile (98.5:1.5, by vol); a flow rate of
1.2ml/min; and a wavelength of 300 nm. The
injection volume was 20 mL. The lower limit of
detection was 0.1 mg/ml in plasma and pleural
fluid.13
At every measurement, assay lines were pre-
pared at concentrations of 50, 25, and 12.5 mg/ml,
and each concentration was calculated.Protein binding
Plasma and pleural fluid from the rabbits induced in
the chemical pleurisy as described above were
used.
Each carbapenem antibiotic agent (30 ml; 200 mg/
ml) was added to 270 ml of rabbit plasma, agitated
and incubated at 37 1C for 30min. Drug-containing
plasma samples were mixed with an equivalent
volume of various stabilizing agents as described
above, and centrifuged in a refrigerated centrifuge
(4 1C 3000 rpm 30min). Filtrate drug levels (A)
were calculated by HPLC. As a control solvent,
an equivalent volume of 1/15M phosphate-buf-
fered isotonic saline (pH 7.4) was used instead of
plasma, and filtrate drug levels (B) were similarly
calculated.
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(30 ml; 200 mg/ml) was added to 270 ml of rabbit
pleural fluid, agitated, and incubated at 37 1C for
30min. Drug-containing pleural fluid samples were
mixed with an equivalent volume of various
stabilizing agents as described above, and centri-
fuged in a refrigerated centrifuge (4 1C
3000 rpm 30min). Filtrate drug levels (A) were
calculated by HPLC. As a control solvent, an
equivalent volume of 1/15M phosphate-buffered
isotonic saline (pH 7.4) was used instead of pleural
fluid, and filtrate drug levels (B) were similarly
calculated.
The rate of protein binding in plasma and pleural
fluid was calculated from the drug concentration
calculated above using the following formula:
protein binding (%) ¼ ðB AÞ=B 100
Measurement of each agent was triplicated.
Pharmacokinetic analysis
Areas under the concentration–time curve (AUC)
over 360min (AUC0–360) for carbapenems were
calculated with the trapezoidal rule. Cmax of the
plasma was calculated as follows: the concentra-
tion of 0min (Cmax) was calculated from the
difference of the concentration of 5min and that
of 10min. Cmax of the pleural fluid was determined
directly from the observed data.
Statistical analysis
For the significance test, the dual-placement var-
iance analysis was performed. When there was a
significant difference, Tukey’s test was used. Statis-
tical significance was defined as a P value o0.05.Results
The plasma and pleural fluid levels of each agent
are shown in Fig. 1a and b.
Plasma Cmax of the test agents (Table 2)
As a single agent (Table 2), IPM achieved the
highest plasma Cmax, 84.5740.7 mg/ml, followed by
BIPM, MEPM, and PAPM. There were no significant
differences in the plasma Cmax of the test agents
among the single agents. Among the drug solution
containing CS, MEPM/CS had the highest plasma
Cmax, 150.5760.0 mg/ml, followed by IPM/CS,
PAPM/CS, and BIPM/CS. There were no significant
differences in the plasma Cmax among these mixed
solutions.Pleural fluid Cmax of the test agents (Table 2)
In two rabbits treated with BIPM as a single agent,
the pleural fluid level of BIPM reached a maximum
60min after infusion. The pleural fluid levels of the
remaining three agents reached a maximum 30min
after infusion. The highest pleural fluid Cmax
(9.473.0 mg/ml) was obtained with PAPM, followed
by BIPM, IPM, and MEPM. The pleural fluid Cmax of
PAPM and BIPM were significantly higher than that
of MEPM. Among the drug solutions containing CS,
the maximum level was reached in 60min in three
rabbits treated with BIPM/CS and in one rabbit
treated with IPM/CS, whereas the maximum level
was reached in 30min in the remaining rabbits.
MEPM/CS had the highest pleural fluid Cmax
(9.874.0 mg/ml), followed by BIPM/CS, PAPM/CS,
and IPM/CS. There were no significant differences
among these mixed solutions.
Pleural fluid Cmax/plasma Cmax ratio (Table 2)
As a single agent, PAPM had the highest pleural fluid
Cmax/plasma Cmax ratio ð0:16 0:06Þ, followed by
BIPM, IPM, and MEPM. The ratio for PAPM was
significantly higher than that for MEPM. Among the
drug solutions containing CS, the ratio for PAPM/CS
was highest ð0:12 0:07Þ, followed by BIPM/CS,
MEPM/CS, and IPM/CS. The ratio for BIPM/CS was
significantly higher than that for IPM/CS.
Plasma AUC0–360 of the test agents (Table 3)
As a single agent (Table 3), BIPM had the highest
plasma AUC0–360 (2684.67362.8 mgmin/ml), fol-
lowed by PAPM, IPM, and MEPM. The plasma
AUC0–360 of BIPM was significantly higher than with
the other three agents. The plasma AUC0–360 of
PAPM was significantly higher than that of MEPM.
Among the drug solutions containing CS, BIPM/CS
had the highest plasma AUC0–360 (3040.17
1525.9 mgmin/ml), followed by PAPM/CS, IPM/CS,
and MEPM/CS. There were no significant differ-
ences among these mixed solutions.
Pleural fluid AUC0–360 of the test agents
(Table 3)
BIPM had the highest pleural fluid AUC0–360
(1247.37224.6 mgmin/ml), followed by PAPM,
MEPM, and IPM. The pleural fluid AUC0–360 of BIPM
was significantly higher than that of MEPM and IPM.
The pleural fluid AUC0–360 of PAPM was significantly
higher than that of IPM. Among the drug solutions
containing CS, MEPM/CS had the highest pleural
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Figure 1 (a) Levels of carbapenem antibiotic agents in the plasma after administration of carbapenems. The plasma
level of IPM was below the detection limit more than 180, 300min after administration of IPM and IPM/CS. The plasma
level of PAPM was below the detection limit more than 300min after administration of PAPM. Other drug levels could be
measured. Each group: n ¼ 3. (b) Levels of carbapenem antibiotic agents in the pleural fluid after administration of
carbapenems. The pleural fluid level of PAPM was below the detection limit more than 300min after administration.
Other drug levels could be measured. Each group: n ¼ 3.
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Table 2 Pharmacokinetic profile of carbapenem antibiotic agents Cmax in the plasma and in the pleural fluid
(each group: n ¼ 3).
Plasma Cmax (mg/ml) Pleural fluid Cmax (mg/ml) Pleural fluid Cmax/Plasma Cmax
Alone +CS Alone +CS Alone +CS
IPM 84.5740.7 119.2728.8 5.470.5 7.071.4 0.0870.05 0.0670.02
PAPM 60.2714.6 87.8744.3 9.473.0a 9.072.2 0.1670.06b 0.1270.07
MEPM 72.4731.7 150.5760.0 3.870.9 9.874.0 0.0670.02 0.0770.01
BIPM 79.2730.0 87.1748.8 7.671.4c 9.372.9 0.1170.06 0.1270.03d
aSignificantly different from MEPM (P ¼ 0:04, Tukey).
bSignificantly different from MEPM (P ¼ 0:004, Tukey).
cSignificantly different from MEPM (P ¼ 0:02, Tukey).
dSignificantly different from IPM (P ¼ 0:04, Tukey).
Table 3 Pharmacokinetic profile of carbapenem antibiotic agents AUC in the plasma and in the pleural fluid
(each group: n ¼ 3).
Plasma AUC0–360 (mgmin/ml) Pleural fluid AUC0–360 (mgmin/ml) Pleural fluid AUC0–360/Plasma AUC0–360
Alone +CS Alone +CS Alone +CS
IPM 1055.37420.3 2193.97881.4 573.2781.8 1062.77206.8a 0.5870.17 0.5170.11
PAPM 1762.67244.2b 2596.87479.3 970.47220.1c 1108.37235.1 0.5570.13 0.4370.03
MEPM 776.37354.6 2033.07747.7 669.27278.8 1594.97510.3 0.8970.13d 0.7970.04e
BIPM 2684.67362.8f 3040.171525.9 1247.37224.6g 1495.77594.0 0.4870.13 0.5170.08
aSignificantly different from IPM (alone) (P ¼ 0:018, Tukey).
bSignificantly different from MEPM (P ¼ 0:02, Tukey).
cSignificantly different from IPM (P ¼ 0:042, Tukey).
dSignificantly different from BIPM (P ¼ 0:002, Tukey) and significantly different from PAPM (P ¼ 0:03, Tukey).
eSignificantly different from PAPM (P ¼ 0:0002, Tukey) and significantly different from BIPM (P ¼ 0:005, Tukey) and
significantly different from IPM (P ¼ 0:01, Tukey).
fSignificantly different from MEPM (P ¼ 0:002, Tukey) and significantly different from IPM (P ¼ 0:007, Tukey) and significantly
different from PAPM (P ¼ 0:02, Tukey).
gSignificantly different from IPM (P ¼ 0:008, Tukey) and significantly different from MEPM (P ¼ 0:048, Tukey).
Pharmacokinetic study of pleural fluid penetration of carbapenem 329fluid AUC0–360 (1594.87510.3 mgmin/ml), followed
by BIPM/CS, PAPM/CS, and IPM/CS. There were no
significant differences among these mixed solu-
tions.Pleural fluid AUC0–360/plasma AUC0–360 ratio
(Table 3)
As a single agent, MEPM had the highest
pleural fluid AUC0–360/plasma AUC0–360 ratio
ð0:89 0:13Þ, followed by IPM, PAPM, and
BIPM. The ratio for MEPM was significantly higher
than that for PAPM and BIPM. Among the drug
solutions containing CS, the ratio for MEPM/CS
was highest ð0:79 0:04Þ, followed by IPM/CS,
BIPM/CS, and PAPM/CS. The ratio for MEPM/CSwas significantly higher than those for the remain-
ing three agents.Influence of CS (Tables 2 and 3)
We compared the test agents alone with the drug
solutions containing CS. CS influenced the AUC of
IPM in pleural fluid via inhibition of DHP-I-related
hydrolysis.Protein binding (Table 4)
The highest rates of protein binding in plasma and
pleural fluid were obtained with MEPM (21.774.2%,
26.172.1%, respectively), followed by IPM, PAPM,
and BIPM. BIPM produced a value significantly lower
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Table 4 Protein binding of carbapenem antibiotic
agents in the plasma and pleural fluid (each group:
n ¼ 3).
Plasma (%) Pleural fluid (%)
IPM 19.671.5a 25.072.8b
PAPM 14.871.3c 18.373.2d
MEPM 21.774.2e 26.172.1f
BIPM 2.371.3 5.773.8
aSignificantly different from BIPM (P ¼ 0:0001, Tukey)
and significantly different from PAPM (P ¼ 0:01, Tukey).
bSignificantly different from BIPM (P ¼ 0:002, Tukey).
cSignificantly different from BIPM (P ¼ 0:0003, Tukey).
dSignificantly different from BIPM (P ¼ 0:01, Tukey).
eSignificantly different from BIPM (P ¼ 0:001, Tukey).
fSignificantly different from BIPM (P ¼ 0:001, Tukey)
and significantly different from PAPM (P ¼ 0:02, Tukey).
T. Niwa et al.330than those of the remaining three agents. PAPM
produced a value significantly lower than IPM.
There was significantly lower pleural fluid protein
binding with BIPM than with the remaining three
agents. A significantly lower value was seen with
PAPM than with MEPM.Discussion
Generally, when agents are dissolved in blood they
are present as free components or are bound to
plasma protein. Release-type components are
diffused passively through the extravascular tissue
to exhibit their pharmacologic actions. In this
study, we measured release-type components alone
by HPLC using an ultrafiltration membrane.
Carbapenem antibiotic agents are hydrolyzed by
DHP-I; however, the amount of hydrolysis differs
among species.14,15 MEPM was easily hydrolyzed by
DHP-I from rabbits,16 but was stable in human. In
clinical practice, CS is contained in carbapenem
antibiotic agents to achieve drug stabilization
against human DHP-I. In this study, CS-containing
solutions of the four agents had a higher plasma
Cmax and plasma AUC than those of the agents
alone, although the differences were not signifi-
cant. PAPM and MEPM, compared with IPM and
BIPM, were rather easily hydrolyzed by DHP-1 from
rabbits, as demonstrated by the large change in the
plasma AUC. This might have been because CS
prevented the influence of rabbit DHP-I-related
hydrolysis on carbapenem antibiotic agents. There-
fore, in this experiment, CS-containing solutions of
the four agents might be appropriate for more
accurate clinical evaluation.Time above MIC is useful for evaluating the
antimicrobial effect because of the time-depen-
dent antimicrobial activity of these agents. But we
could not calculate time above MIC, because this
study did not use the infection models. Therefore,
we investigated the Cmax and AUC which are
correlated with the total drug levels in vivo. Briefly,
the ratio pleural fluid AUC/plasma AUC correlates
with the penetration of a drug in the pleural space;
therefore, it might be a useful index of pleural fluid
penetration.
Molecular weight, presence or absence of lipo-
solubility,17 and protein binding18,19 are important
for the penetration of antimicrobial agents. Drugs
with a lower molecular weight have better pene-
tration. With respect to the presence or absence of
fat solubility, many agents consist of slightly acidic
organic acids or weak bases, and are present as
non-ionic and ionic substances in a water environ-
ment. Non-ionic substances are fat soluble; they
rapidly pass through the cell membrane, and are
diffused. In comparison to non-ionic substances,
however, ionic substances have poor diffusion due
to electrical impedance related to the charge on
the cell membrane. There were no marked differ-
ences in the molecular weights of IPM, PAPM,
MEPM, and BIPM (i.e., 317, 339, 437, and 380,
respectively). Furthermore, all carbapenem anti-
biotic agents consist of weak bases, and are present
in blood as ionic substances, which might have
resulted in the absence of marked differences.
Concerning protein binding, the binding rate is low
in rabbit peripheral lymph18 or subcutaneous
Visking Chamber19 penetration, and penetration is
better when the proportion of release-type com-
ponents is higher.
Both MEPM alone and MEPM/CS had a high rate of
pleural fluid penetration as demonstrated by the
AUC measurements. As a single agent, PAPM
produced the highest pleural fluid Cmax and BIPM
had the highest pleural fluid AUC. Among the drug
solutions containing CS, however, MEPM produced
both the highest pleural fluid Cmax and the pleural
fluid AUC. This might have been because the
addition of CS eliminated the influence of DHP-I-
related hydrolysis, maintaining the blood MEPM
level and improving pleural fluid penetration in
comparison to MEPM alone, as MEPM is unstable
against rabbit DHP-I.15 Both MEPM alone and MEPM/
CS had a high rate of pleural fluid penetration.
Cephem agents with a low protein-binding rate
have good lymph and subcutaneous chamber
penetration. In the present experiment, however,
MEPM, with the highest protein binding rate, had
the most favorable pleural fluid penetration,
suggesting that the rate of protein binding is not
ARTICLE IN PRESS
Pharmacokinetic study of pleural fluid penetration of carbapenem 331useful for evaluating pleural fluid penetration of
carbapenem antibiotic agents.Conclusion
In the present study, MEPM had the most favo-
rable pleural fluid penetration, although it is
necessary to study the pleural fluid penetration
in various infection models and clinical trials.
AUC may play the role of a useful maker for
evaluating the bactericidal effect of b lactam
antibiotics.References
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